Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: Final analysis of a phase 2 study

Blood

Volumn 126, Issue 11, 2015, Pages 1392-1394

  Kastritis, Efstathios ^a   Gavriatopoulou, Maria ^a   Kyrtsonis, Marie Christine ^b   Roussou, Maria ^a   Hadjiharissi, Evdoxia ^c   Symeonidis, Argyris ^d   Repoussis, Panagiotis ^e   Michalis, Evridiki ^f   Delimpasi, Sosana ^g   Tsatalas, Konstantinos ^h   Tsirigotis, Panagiotis ^b   Vassou, Amalia ⁱ   Vervessou, Elina ^j   Katodritou, Eirini ^c   Gika, Dimitra ^a   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e METAXA Cancer Memorial Hospital   (Greece)

^f G GENNIMATAS GENERAL HOSPITAL   (Greece)

^g EVANGELISMOS HOSPITAL   (Greece)

^h DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

ⁱ UNIVERSITY OF IOANNINA   (Greece)

^j HENRY DUNANT HOSPITAL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER PATIENT; DISEASE COURSE; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; RITUXIMAB; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84942526164     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-647420     Document Type: Letter

References (10)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
2. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):116-120.
3. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349.
4. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):127-131.
5. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009;147(5):677-680.
6. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3282.
7. Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
8. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301-307.
9. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250-255.
10. Leblond V, Lévy V, Maloisel F, et al; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640-2644.